- Hereditary Breast and Ovarian Cancer syndrome (HBOC)
- Lynch syndrome/Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
- Familial Adenomatous Polyposis (FAP)/Attenuated Familial Adenomatous Polyposis (AFAP)
- MUTYH-associated Polyposis syndrome (MAP)
- MUTYH-associated Colon Cancer Risk
- Melanoma Cancer Syndrome (MCS)
- Li-Fraumeni Syndrome (LFS)
- PTEN Hamartoma Tumor syndrome (PHTS)
- Peutz-Jeghers Syndrome
- Hereditary Diffuse Gastric Cancer (HDGC) Syndrome
- Juvenile Polyposis Syndrome (JPS)
- Juvenile Polyposis Syndrome (JPS) and Hereditary Hemorrhagic Telangiectasia (HHT)
- PALB2-associated Cancer Risk
- CHEK2-associated Cancer Risk
- ATM-associated Cancer Risk
- NBN-associated Cancer Risk
- BARD1-associated Cancer Risk
- BRIP1-associated Cancer Risk
- RAD51C-associated Cancer Risk
- RAD51D-associated Cancer Risk
- Polymerase Proofreading-associated Syndrome (PPAS)
- Hereditary Mixed Polyposis Syndrome (HMPS)
RAD51C ASSOCIATED CANCER RISKS
RAD51C ASSOCIATED CANCER RISKS
What does it mean to have a RAD51C gene mutation?
Women with mutations in the RAD51C gene have an increased risk for breast and ovarian cancer. Researchers have only recently learned about cancer risk associated with RAD51C, and the exact cancer risks are unknown. There are signs that the risk might be higher for women who have a RAD51C mutation and who also have relatives who have had breast and/or ovarian cancer.
At this time, we do not know of any cancer risks for men with RAD51C mutations.
What can be done to protect women with RAD51C mutations from cancer?
At this time, there are no standard recommendations for lowering the risk of breast and ovarian cancer in women with mutations in RAD51C. However, women with mutations in RAD51C can talk with their doctors and other healthcare providers about possible individualized recommendations such as special screening or, in the case of ovarian cancer, preventative surgery.
Associated Syndrome Name: RAD51C-associated Cancer Risk (Women only)
RAD51C Summary Cancer Risk Table
|Cancer||Genetic Cancer Risk|
RAD51C gene Overview
RAD51C-associated Cancer Risk (Women only) 1, 2, 3, 4
- Women with RAD51C mutations have an increased risk for ovarian cancer. Although the actual increase in risk is currently estimated to be moderate in size, there are some indications that the risk for ovarian cancer might be higher in families in which there is a past history of ovarian cancer.
- Women with RAD51C mutations may have a risk for breast cancer that is increased over the 12.5% lifetime risk for women in the general population of the United States. Evidence for this increased risk for female breast cancer is strongest in families where there is a past history of both breast and ovarian cancer. However, this evidence is not conclusive and there are currently no medical management guidelines to address this possible risk.
- At this time, there are no known cancer risks for men due to mutations in RAD51C.
- Although there are high cancer risks for patients with mutations in RAD51C, there are interventions that may be effective at reducing these risks. Guidelines from the National Comprehensive Cancer Network (NCCN) that may apply are listed below. Since information about the cancer risks associated with RAD51C mutations is relatively new, and there is still some uncertainty about the best ways to reduce these risks, it may be appropriate to interpret these results in consultation with cancer genetics experts in this emerging area of knowledge.
RAD51C gene Cancer Risk Table
|Cancer Type||Age Range||Cancer Risk||Risk for General Population|
|Ovarian||To age 504, 5||1.0%||0.2%|
|To age 801, 2, 3, 4, 5||6.7%||1.0%|
RAD51C Cancer Risk Management Table
The overview of medical management options provided is a summary of professional society guidelines as of the last Myriad update shown on this page. The specific reference provided (e.g., NCCN guidelines) should be consulted for more details and up-to-date information before developing a treatment plan for a particular patient.
This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient’s personal medical history, surgeries and other treatments.
|Cancer Type||Procedure||Age to Begin||Frequency |
(Unless otherwise indicated by findings)
|Ovarian||Consider bilateral salpingo-oophorectomy (BSO).6||45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age||NA|
|Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.6||Individualized||NA|
Information for Family Members
The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the RAD51C gene.
A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions.
In rare instances, an individual may inherit mutations in both copies of the RAD51C gene, which may lead to a Fanconi Anemia-like disorder. This condition has only been seen in 2 siblings with physical abnormalities, short stature and abnormal chromosome breakage test results. The children of this patient are at risk of inheriting this condition only if the other parent is also a carrier of a RAD51C mutation. This is highly unlikely, due to the rarity of RAD51C mutations.7
At this time, there are no known cancer risks for men due to mutations in RAD51C.
- Meindl A, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010 42:410-4. PubMed PMID: 20400964.
- Loveday C, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet. 2012 44:475-6. PMID: 22538716.
- Pelttari LM, et al. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet. 2011 20:3278-88. PMID: 21616938.
- Song H, et al. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol. 2015 10:2901-7. PMID: 26261251.
- Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/faststats. (Accessed on 1-2-2017)
- Daly M et al. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V 2.2019. July 30. Available at http://www.nccn.org.
- Vaz F, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010 42:406-9. PMID: 20400963.
Last Updated on 09-Jul-2019